X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration is created to pursue a novel method to enhance Integra's ability to use gene editing for future cancer therapies. Predictive Oncology has protein expression experience and unique ability to optimize solubility and physical stability for expressed proteins.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Integra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2023
Details:
The collaboration utilizes Predictive Oncology’s PEDAL technology to evaluate Cancer Research Horizons’ pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient populations are most likely to respond to treatment with these compounds.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undislcosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cancer Research Horizons
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 17, 2023
Details:
By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities, and the Cvergenx precision genomics radiation therapy platform (pGRT™), the two companies will pursue ways in which to optimize genomically-guided radiation therapy.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cvergenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 23, 2023
Details:
The acquisition immediately adds a new anticipated revenue stream to Predictive Oncology and contributes to the company’s larger mission of supporting the development of new cancer therapies from drug discovery through regulatory approval.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: zPREDICTA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 01, 2021
Details:
The Company intends to use up to approximately $5.88 million of the net proceeds to repay certain indebtedness and the remainder of the net proceeds for general corporate purposes.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: H.C. Wainwright & Co
Deal Size: $17.6 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 23, 2021
Details:
Integrating QM’s proven machine learning platform, CoRE, with Predictive Oncology's proprietary database of drug response and genomics profiles is expected to revolutionize the role of its AI-driven predictive models in the discovery and development of new anti-cancers.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Quantitative Medicine
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Acquisition July 07, 2020
Details:
POAI has signed an agreement with Dr. Carter in which POAI licenses a ground-breaking vaccine technology developed by Dr. Carter based on an NSP-10 self-assembled nanoparticle.
Lead Product(s): NSP-10 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Dr. Daniel Carter
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
